Base de dados : MEDLINE
Pesquisa : D02.886.675.215 [Categoria DeCS]
Referências encontradas : 1551 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 156 ir para página                         

  1 / 1551 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28456772
[Au] Autor:Sano T; Utsumi D; Amagase K; Matsumoto K; Tominaga M; Higuchi K; Takeuchi T; Kato S
[Ad] Endereço:Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Yamashina, Kyoto, Japan. beatatsuo0507@gmail.com.
[Ti] Título:Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons.
[So] Source:J Physiol Pharmacol;68(1):79-90, 2017 Feb.
[Is] ISSN:1899-1505
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Intestinal mucositis accompanied by severe diarrhea is one of the most common side effects during cancer chemotherapy. Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties via sensory afferent neurons, is used for the treatment of upper gastrointestinal diseases. The present study investigated the effects of lafutidine on 5-fluorouracil (5-FU)-induced intestinal mucositis induced in mice. Male C57BL/6 wild-type (WT), sensory deafferented mice, and transient receptor potential vanilloid subfamily 1 knockout (TRPV1KO) mice were used. Animals were administered 5-FU once daily, while lafutidine and famotidine were administered twice daily for 6 days. Repeated administration of 5-FU caused severe intestinal mucositis, characterized by shortening of villi and destruction of crypts and was accompanied by diarrhea and body weight loss. Daily administration of lafutidine reduced the severity of intestinal mucositis, diarrhea and body weight loss in a dose-dependent manner, while famotidine had no effect on intestinal mucositis. The preventive effects of lafutidine were completely abolished in sensory deafferented and TRPV1-KO mice. Lafutidine significantly suppressed 5-FU-increased MPO activity and inflammatory cytokine expression on day 6, but not apoptosis induction in intestinal crypts on day 1. Lafutidine induced Alcian Blue and PAS-positive mucus production in the small intestine. These findings suggest that lafutidine attenuates 5-FU-induced intestinal mucositis, most likely by increasing mucus production via activation of sensory afferent neurons. Furthermore, intact TRPV1 signaling is essential for the activation of sensory afferent neurons induced by lafutidine. Therefore, lafutidine is more useful than other common antacids for the treatment of intestinal mucositis during cancer chemotherapy.
[Mh] Termos MeSH primário: Acetamidas/uso terapêutico
Diarreia/tratamento farmacológico
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Mucosite/tratamento farmacológico
Piperidinas/uso terapêutico
Piridinas/uso terapêutico
[Mh] Termos MeSH secundário: Acetamidas/farmacologia
Animais
Antimetabólitos Antineoplásicos
Diarreia/metabolismo
Diarreia/patologia
Famotidina/uso terapêutico
Fluoruracila
Antagonistas dos Receptores Histamínicos H2/farmacologia
Interleucina-1beta/genética
Intestinos/efeitos dos fármacos
Intestinos/metabolismo
Intestinos/patologia
Masculino
Camundongos Endogâmicos C57BL
Camundongos Knockout
Mucosite/induzido quimicamente
Mucosite/patologia
Peroxidase/metabolismo
Piperidinas/farmacologia
Piridinas/farmacologia
RNA Mensageiro/metabolismo
Fator de Necrose Tumoral alfa/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetamides); 0 (Antimetabolites, Antineoplastic); 0 (Histamine H2 Antagonists); 0 (IL1B protein, mouse); 0 (Interleukin-1beta); 0 (Piperidines); 0 (Pyridines); 0 (RNA, Messenger); 0 (Tumor Necrosis Factor-alpha); 49S4O7ADLC (lafutidine); 5QZO15J2Z8 (Famotidine); EC 1.11.1.7 (Peroxidase); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  2 / 1551 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773524
[Au] Autor:Viciosa MT; Moura Ramos JJ; Diogo HP
[Ad] Endereço:Centro de Química-Física Molecular and Institute of Nanoscience and Nanotechnology, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
[Ti] Título:The Slow Relaxation Dynamics in the Amorphous Pharmaceutical Drugs Cimetidine, Nizatidine, and Famotidine.
[So] Source:J Pharm Sci;105(12):3573-3584, 2016 Dec.
[Is] ISSN:1520-6017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The slow molecular mobility in the amorphous solid state of 3 active pharmaceutical drugs (cimetidine, nizatidine, and famotidine) has been studied using differential scanning calorimetry and the 2 dielectric-related techniques of dielectric relaxation spectroscopy and thermally stimulated depolarization currents. The glass-forming ability, the glass stability, and the tendency for crystallization from the equilibrium melt were investigated by differential scanning calorimetry, which also provided the characterization of the main relaxation of the 3 glass formers. The chemical instability of famotidine at the melting temperature and above it prevented the preparation of the amorphous for dielectric studies. In contrast, for cimetidine and nizatidine, the dielectric study yielded the main kinetic features of the α relaxation and of the secondary relaxations. According to the obtained results, nizatidine displays the higher fragility index of the 3 studied glass-forming drugs. The thermally stimulated depolarization current technique has proved useful to identify the Johari-Goldstein relaxation and to measure τ in the amorphous solid state, that is, in a frequency range which is not easily accessible by dielectric relaxation spectroscopy.
[Mh] Termos MeSH primário: Química Farmacêutica/métodos
Cimetidina/química
Famotidina/química
Nizatidina/química
[Mh] Termos MeSH secundário: Varredura Diferencial de Calorimetria/métodos
Cimetidina/metabolismo
Famotidina/metabolismo
Nizatidina/metabolismo
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
5QZO15J2Z8 (Famotidine); 80061L1WGD (Cimetidine); P41PML4GHR (Nizatidine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  3 / 1551 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28151040
[Au] Autor:Mokhtar M; Gosselin P; Lacasse F; Hildgen P
[Ad] Endereço:a Faculty of Pharmacy , University of Montreal , Montreal , Quebec , Canada.
[Ti] Título:Design of PEG-grafted-PLA nanoparticles as oral permeability enhancer for P-gp substrate drug model Famotidine.
[So] Source:J Microencapsul;34(1):91-103, 2017 Feb.
[Is] ISSN:1464-5246
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Bioavailability of oral drugs can be limited by an intestinal excretion process mediated by P-glycoprotein (P-gp). Polyethylene glycol (PEG) is a known P-gp inhibitor. Dispersion of Famotidine (a P-gp substrate) within PEGylated nanoparticles (NPs) was used to improve its oral bioavailability. In this work, we evaluated the potential impact of NPs prepared from a grafted copolymer of polylactic acid and PEG on P-gp function by studying in vitro permeability of Famotidine across Caco-2 cells. Copolymers of PEG grafted on polylactic acid (PLA) backbone (PLA-g-PEG) were synthesised with 1 mol% and 5 mol% PEG vs. lactic acid monomer using PEG 750 and 2000 Da. The polymers were used to prepare Famotidine-loaded NPs and tested in vitro on Caco-2 cells. Significant decrease in basolateral-to-apical transport of Famotidine was observed when Famotidine was encapsulated in NPs prepared from PLA-g-PEG5%. NPs prepared from PLA-g-PEG5% are promising to improve oral bioavailability of P-gp substrates.
[Mh] Termos MeSH primário: Portadores de Fármacos/química
Famotidina/administração & dosagem
Famotidina/farmacocinética
Antagonistas dos Receptores Histamínicos H2/administração & dosagem
Antagonistas dos Receptores Histamínicos H2/farmacocinética
Nanopartículas/química
Poliésteres/química
Polietilenoglicóis/química
[Mh] Termos MeSH secundário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo
Células CACO-2
Famotidina/metabolismo
Antagonistas dos Receptores Histamínicos H2/metabolismo
Seres Humanos
Permeabilidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ATP-Binding Cassette, Sub-Family B, Member 1); 0 (Drug Carriers); 0 (Histamine H2 Antagonists); 0 (Polyesters); 30IQX730WE (Polyethylene Glycols); 459TN2L5F5 (poly(lactide)); 5QZO15J2Z8 (Famotidine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170203
[St] Status:MEDLINE
[do] DOI:10.1080/02652048.2017.1290155


  4 / 1551 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28085074
[Au] Autor:Laudy AE; Kulinska E; Tyski S
[Ad] Endereço:Department of Pharmaceutical Microbiology, Medical University of Warsaw, Oczki 3 Str., 02-007 Warsaw, Poland. alaudy@wp.pl.
[Ti] Título:The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.
[So] Source:Molecules;22(1), 2017 Jan 11.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The potential role of non-antibiotic medicinal products in the treatment of multidrug-resistant Gram-negative bacteria has recently been investigated. It is highly likely that the presence of efflux pumps may be one of the reasons for the weak activity of non-antibiotics, as in the case of some non-steroidal anti-inflammatory drugs (NSAIDs), against Gram-negative rods. The activity of eight drugs of potential non-antibiotic activity, active substance standards, and relevant medicinal products were analysed with and without of efflux pump inhibitors against 180 strains of five Gram-negative rod species by minimum inhibitory concentration (MIC) value determination in the presence of 1 mM MgSO4. Furthermore, the influence of non-antibiotics on the susceptibility of clinical strains to quinolones with or without PAßN (Phe-Arg-ß-naphthylamide) was investigated. The impacts of PAßN on the susceptibility of bacteria to non-antibiotics suggests that amitriptyline, alendronate, nicergoline, and ticlopidine are substrates of efflux pumps in Gram-negative rods. Amitriptyline/Amitriptylinum showed the highest direct antibacterial activity, with MICs ranging 100-800 mg/L against all studied species. Significant decreases in the MIC values of other active substances (acyclovir, atorvastatin, and famotidine) tested with pump inhibitors were not observed. The investigated non-antibiotic medicinal products did not alter the MICs of quinolones in the absence and in the presence of PAßN to the studied clinical strains of five groups of species.
[Mh] Termos MeSH primário: Amitriptilina/farmacologia
Antibacterianos/farmacologia
Dipeptídeos/farmacologia
Genes MDR/efeitos dos fármacos
Pseudomonas aeruginosa/efeitos dos fármacos
[Mh] Termos MeSH secundário: Aciclovir/farmacologia
Alendronato/farmacologia
Atorvastatina Cálcica/farmacologia
Combinação de Medicamentos
Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos
Farmacorresistência Bacteriana Múltipla/genética
Escherichia coli/efeitos dos fármacos
Escherichia coli/crescimento & desenvolvimento
Escherichia coli/metabolismo
Famotidina/farmacologia
Klebsiella pneumoniae/efeitos dos fármacos
Klebsiella pneumoniae/crescimento & desenvolvimento
Klebsiella pneumoniae/metabolismo
Sulfato de Magnésio/farmacologia
Testes de Sensibilidade Microbiana
Nicergolina/farmacologia
Pseudomonas aeruginosa/crescimento & desenvolvimento
Pseudomonas aeruginosa/metabolismo
Quinolonas/farmacologia
Salmonella/efeitos dos fármacos
Salmonella/crescimento & desenvolvimento
Salmonella/metabolismo
Ticlopidina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Dipeptides); 0 (Drug Combinations); 0 (Quinolones); 0 (phenylalanylarginine-naphthylamide); 1806D8D52K (Amitriptyline); 48A5M73Z4Q (Atorvastatin Calcium); 5QZO15J2Z8 (Famotidine); 7487-88-9 (Magnesium Sulfate); JCV8365FWN (Nicergoline); OM90ZUW7M1 (Ticlopidine); X1J18R4W8P (Alendronate); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170515
[Lr] Data última revisão:
170515
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170114
[St] Status:MEDLINE


  5 / 1551 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27922030
[Au] Autor:Hsu PI; Wu DC; Tsay FW; Cheng JS; Liu CP; Lai KH; Chen WC; Wang HM; Tsai TJ; Tsai KW; Kao SS
[Ad] Endereço:Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan.
[Ti] Título:Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
[So] Source:Am J Gastroenterol;112(2):282-289, 2017 Feb.
[Is] ISSN:1572-0241
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Proton pump inhibitor can effectively prevent recurrent peptic ulcers among atherosclerotic patients receiving clopidogrel monotherapy. However, the interaction between proton pump inhibitors and clopidogrel has raised concerns over the safety of combined use of the two medicines in clinical practice. The aims of this randomized-controlled, double-blind and double-dummy trial were to investigate the efficacy of histamine-2 receptor antagonist (H2RA) in the prevention of recurrent peptic ulcer in patients undergoing thienopyridine monotherapy. METHODS: From January 2012 to 2016, long-termed thienopyridine users with a peptic ulcer history who did not have peptic ulcers at initial endoscopy were randomly assigned to receive either famotidine (40 mg, before bedtime) or placebo (before bedtime) for 6 months. Follow-up endoscopy was performed at the end of the 6th month and whenever dyspepsia, hematemesis, or melena occurred. RESULTS: The cumulative incidence of recurrent peptic ulcer during the 6-month period was 7.0% in famotidine group (n=114) and 11.4% in the placebo group (n=114). The two patient groups had comparable cumulative incidence of peptic ulcer (difference, 4.4%; 95% confidence interval (CI), -11.7 to 2.9%; P=0.239). Additionally, there was no difference in the cumulative incidence of ulcer bleeding (2.6% vs. 1.8%; difference, 0.8%; 95% CI, -0.6 to 2.4%, P=1.000) between famotidine and placebo groups. However, the former had a lower incidence of gastroduodenal erosion than the latter (21.1% vs. 36.8%; difference, 15.7%; 95% CI, -27.3 to -4.1%; P=0.013). CONCLUSIONS: Famotidine cannot decrease the incidence of peptic ulcer or ulcer bleeding in thienopyridine users with atherosclerotic disease and a history of peptic ulcer.
[Mh] Termos MeSH primário: Aterosclerose/tratamento farmacológico
Famotidina/uso terapêutico
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Úlcera Péptica Hemorrágica/prevenção & controle
Úlcera Péptica/prevenção & controle
Antagonistas do Receptor Purinérgico P2Y/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antibacterianos/uso terapêutico
Aterosclerose/complicações
Método Duplo-Cego
Feminino
Infecções por Helicobacter/complicações
Infecções por Helicobacter/tratamento farmacológico
Seres Humanos
Masculino
Meia-Idade
Úlcera Péptica/induzido quimicamente
Inibidores da Bomba de Prótons/uso terapêutico
Recidiva
Ticlopidina/efeitos adversos
Ticlopidina/análogos & derivados
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Histamine H2 Antagonists); 0 (Proton Pump Inhibitors); 0 (Purinergic P2Y Receptor Antagonists); 5QZO15J2Z8 (Famotidine); A74586SNO7 (clopidogrel); OM90ZUW7M1 (Ticlopidine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170620
[Lr] Data última revisão:
170620
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161207
[St] Status:MEDLINE
[do] DOI:10.1038/ajg.2016.526


  6 / 1551 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27817104
[Au] Autor:Gavioli E; Abrams M
[Ad] Endereço:Department of Pharmacy, Indiana University Health, 601 W. Second St., Bloomington, IN, 47403, USA. egavioli@kingsbrook.org.
[Ti] Título:Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade.
[So] Source:Support Care Cancer;25(3):817-822, 2017 Mar.
[Is] ISSN:1433-7339
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Febrile neutropenia (FN) is an oncological emergency that may reduce patient survival due to chemotherapy dose delays or reductions. It is recommended that patients at risk for FN receive prophylaxis with granulocyte-colony stimulating factor (G-CSF). Bone pain is a common side effect through a mechanism not fully understood. It is thought to be due to histamine release from an inflammatory response. METHODS: This was a retrospective cohort from January to November 2015. Oncology patients receiving an initial dose of G-CSFs rated their bone pain on a 0-10 scale prior to starting each cycle of chemotherapy and at least 1 day after G-CSF had been given. Those who developed bone pain received prophylaxis at their next G-CSF dose with a combination of famotidine and loratadine. The primary endpoint was to determine the analgesic effects of double histamine blockade for G-CSF induced bone pain. The secondary endpoint was to determine potential risk factors for the development of bone pain. RESULTS: Thirty percent of patients developed bone pain within this cohort, and 17 patients were included in the final analysis. Bone pain scores were lower by a mean of 1.21[(0.20-2.23), p = 0.019] in patients who were prophylaxed with the double histamine blockade. Type of cancer, treatment, age, and BMI were not significant predictors of bone pain. CONCLUSION: The use of a double histamine blockade is an inexpensive, safe, and effective way to alleviate bone pain symptoms secondary to G-CSF agents. Further investigation is warranted for prospective larger studies to confirm these results.
[Mh] Termos MeSH primário: Doenças Ósseas/induzido quimicamente
Doenças Ósseas/prevenção & controle
Fator Estimulador de Colônias de Granulócitos/efeitos adversos
Antagonistas dos Receptores Histamínicos/uso terapêutico
Dor Musculoesquelética/induzido quimicamente
Dor Musculoesquelética/prevenção & controle
[Mh] Termos MeSH secundário: Idoso
Antineoplásicos/administração & dosagem
Antineoplásicos/efeitos adversos
Estudos de Coortes
Famotidina/uso terapêutico
Neutropenia Febril/prevenção & controle
Feminino
Fator Estimulador de Colônias de Granulócitos/uso terapêutico
Seres Humanos
Loratadina/uso terapêutico
Masculino
Meia-Idade
Neoplasias/tratamento farmacológico
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Histamine Antagonists); 143011-72-7 (Granulocyte Colony-Stimulating Factor); 5QZO15J2Z8 (Famotidine); 7AJO3BO7QN (Loratadine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161107
[St] Status:MEDLINE
[do] DOI:10.1007/s00520-016-3465-y


  7 / 1551 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27641510
[Au] Autor:Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
[Ad] Endereço:Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong. Electronic address: fklchan@cuhk.edu.hk.
[Ti] Título:Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
[So] Source:Gastroenterology;152(1):105-110.e1, 2017 Jan.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: It is not clear whether H -receptor antagonists (H2RAs) reduce the risk of gastrointestinal (GI) bleeding in aspirin users at high risk. We performed a double-blind randomized trial to compare the effects of a proton pump inhibitor (PPI) vs a H2RA antagonist in preventing recurrent upper GI bleeding and ulcers in high-risk aspirin users. METHODS: We studied 270 users of low-dose aspirin (≤325 mg/day) with a history of endoscopically confirmed ulcer bleeding at 8 sites in Hong Kong and Japan. After healing of ulcers, subjects with negative results from tests for Helicobacter pylori resumed aspirin (80 mg) daily and were assigned randomly to groups given a once-daily PPI (rabeprazole, 20 mg; n = 138) or H2RA (famotidine, 40 mg; n = 132) for up to 12 months. Subjects were evaluated every 2 months; endoscopy was repeated if they developed symptoms of upper GI bleeding or had a reduction in hemoglobin level greater than 2 g/dL and after 12 months of follow-up evaluation. The adequacy of upper GI protection was assessed by end points of recurrent upper GI bleeding and a composite of recurrent upper GI bleeding or recurrent endoscopic ulcers at month 12. RESULTS: During the 12-month study period, upper GI bleeding recurred in 1 patient receiving rabeprazole (0.7%; 95% confidence interval [CI], 0.1%-5.1%) and in 4 patients receiving famotidine (3.1%; 95% CI, 1.2%-8.1%) (P = .16). The composite end point of recurrent bleeding or endoscopic ulcers at month 12 was reached by 9 patients receiving rabeprazole (7.9%; 95% CI, 4.2%-14.7%) and 13 patients receiving famotidine (12.4%; 95% CI, 7.4%-20.4%) (P = .26). CONCLUSIONS: In a randomized controlled trial of users of low-dose aspirin at risk for recurrent GI bleeding, a slightly lower proportion of patients receiving a PPI along with aspirin developed recurrent bleeding or ulcer than of patients receiving an H2RA with the aspirin, although this difference was not statistically significant. ClincialTrials.gov no: NCT01408186.
[Mh] Termos MeSH primário: Aspirina/efeitos adversos
Famotidina/uso terapêutico
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Úlcera Péptica Hemorrágica/prevenção & controle
Úlcera Péptica/prevenção & controle
Inibidores da Agregação de Plaquetas/efeitos adversos
Inibidores da Bomba de Prótons/uso terapêutico
Rabeprazol/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Aspirina/administração & dosagem
Método Duplo-Cego
Feminino
Hemoglobinas/metabolismo
Seres Humanos
Masculino
Meia-Idade
Úlcera Péptica Hemorrágica/sangue
Inibidores da Agregação de Plaquetas/administração & dosagem
Recidiva
Fatores de Risco
Prevenção Secundária
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Hemoglobins); 0 (Histamine H2 Antagonists); 0 (Platelet Aggregation Inhibitors); 0 (Proton Pump Inhibitors); 32828355LL (Rabeprazole); 5QZO15J2Z8 (Famotidine); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160920
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  8 / 1551 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27608003
[Au] Autor:Yin H; Wang R; Wan J; Zheng Y; Ouyang D; Wang R
[Ad] Endereço:State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau 999078, China. hyin531@outlook.com.
[Ti] Título:Molecular Encapsulation of Histamine H2-Receptor Antagonists by Cucurbit[7]Uril: An Experimental and Computational Study.
[So] Source:Molecules;21(9), 2016 Sep 06.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The histamine H2-receptor antagonists cimetidine, famotidine and nizatidine are individually encapsulated by macrocyclic cucurbit[7]uril (CB[7]), with binding affinities of 6.57 (±0.19) × 10³ M(-1), 1.30 (±0.27) × 104 M(-1) and 1.05 (±0.33) × 105 M(-1), respectively. These 1:1 host-guest inclusion complexes have been experimentally examined by ¹H-NMR, UV-visible spectroscopic titrations (including Job plots), electrospray ionization mass spectrometry (ESI-MS), and isothermal titration calorimetry (ITC), as well as theoretically by molecular dynamics (MD) computation. This study may provide important insights on the supramolecular formulation of H2-receptor antagonist drugs for potentially enhanced stability and controlled release based on different binding strengths of these host-guest complexes.
[Mh] Termos MeSH primário: Hidrocarbonetos Aromáticos com Pontes/química
Cimetidina/química
Famotidina/química
Antagonistas dos Receptores Histamínicos H2/química
Imidazóis/química
Simulação de Dinâmica Molecular
Nizatidina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bridged-Ring Compounds); 0 (Histamine H2 Antagonists); 0 (Imidazoles); 0 (cucurbit(7)uril); 5QZO15J2Z8 (Famotidine); 80061L1WGD (Cimetidine); P41PML4GHR (Nizatidine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160909
[St] Status:MEDLINE


  9 / 1551 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27443665
[Au] Autor:Zhao F; Wang S; Liu L; Wang Y
[Ti] Título:Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis.
[So] Source:Int J Clin Pharmacol Ther;54(10):761-70, 2016 Oct.
[Is] ISSN:0946-1965
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:To evaluate the efficacy of members of the H2RA family for the treatment of gastro-esophageal reflux disease (GERD). We performed a thorough electronic search on PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) for eligible randomized clinical trials that investigated H2RAs and the treatment of GERD up to July 28, 2015. A comprehensive network meta-analysis was conducted to compare the effects of each subset of H2RAs. A total of 13 randomized controlled trials (RCTs) were included in our network meta-analysis. Our results showed that, compared with placebos, H2RAs were more effective for the treatment of GERD. Within the H2RA family, famotidine 80 mg per day (OR = 0.17, 95% CI: 0.06 - 0.38) was determined to be the most effective, followed by famotidine 40 mg per day (odds ratio (OR) = 0.23, 95% confidence interval (CI), 0.11 - 0.44); ranitidine 1,200 mg per day (OR, 0.32; 95% CI, 0.13 - 0.63); ranitidine 600 mg per day (OR, 0.27; 95% CI, 0.14 - 0.47); ranitidine 300 mg per day (OR, 0.31; 95% CI, 0.15 - 0.55); cimetidine 1,600 mg per day (OR, 0.36; 95% CI, 0.14 - 0.73); nizatidine 600 mg per day (OR, 0.58; 95% CI, 0.24 - 1.24); and finally nizatidine 300 mg per day (OR, 0.61; 95% CI, 0.25 - 1.26). The placebo was determined to be the least effective treatment. Compared with other H2RAs, famotidine had the best short-term therapeutic effect in adults with GERD, especially at a dosage of 80 mg per day.
[Mh] Termos MeSH primário: Refluxo Gastroesofágico/tratamento farmacológico
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Relação Dose-Resposta a Droga
Famotidina/administração & dosagem
Famotidina/uso terapêutico
Antagonistas dos Receptores Histamínicos H2/administração & dosagem
Seres Humanos
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Histamine H2 Antagonists); 5QZO15J2Z8 (Famotidine)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170111
[Lr] Data última revisão:
170111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160723
[St] Status:MEDLINE
[do] DOI:10.5414/CP202564


  10 / 1551 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27174372
[Au] Autor:Pahs L; Droege C; Kneale H; Pancioli A
[Ad] Endereço:University of Cincinnati Medical Center, Cincinnati, OH. Electronic address: lpahs@hotmail.com.
[Ti] Título:A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.
[So] Source:Ann Emerg Med;68(3):345-8, 2016 Sep.
[Is] ISSN:1097-6760
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Orolingual angioedema is a rare adverse effect of tissue plasminogen activator (tPA), with an incidence of 1% to 5%. There are currently no published reports describing resolution of tPA-induced orolingual angioedema with complement inhibitor therapy. A 72-year-old man receiving home angiotensin-converting enzyme inhibitor therapy presented to the emergency department with newly developed orolingual angioedema after treatment with tPA for acute ischemic stroke. Therapy was initiated with intravenous methylprednisolone 125 mg, famotidine 20 mg, and diphenhydramine 50 mg, without significant improvement. Because of increased concern for airway protection, plasma-derived C1 esterase inhibitor was administered. Concerns about progressive and airway-threatening orolingual angioedema subsided 2 hours after administration, and invasive airway maneuvers were avoided. Orolingual angioedema is an infrequent, severe adverse effect of tPA for treatment of acute ischemic stroke. Complement inhibitors may be an additional therapeutic option for patients presenting with orolingual angioedema with potential airway compromise that is refractory to standard anaphylactic therapies.
[Mh] Termos MeSH primário: Angioedema/induzido quimicamente
Doenças da Boca/induzido quimicamente
Ativador de Plasminogênio Tecidual/efeitos adversos
Doenças da Língua/induzido quimicamente
[Mh] Termos MeSH secundário: Idoso
Angioedema/terapia
Anti-Inflamatórios/administração & dosagem
Anti-Inflamatórios/uso terapêutico
Difenidramina/administração & dosagem
Difenidramina/uso terapêutico
Quimioterapia Combinada
Famotidina/administração & dosagem
Famotidina/uso terapêutico
Antagonistas dos Receptores Histamínicos H1/administração & dosagem
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Antagonistas dos Receptores Histamínicos H2/administração & dosagem
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Seres Humanos
Injeções Intravenosas
Masculino
Metilprednisolona/administração & dosagem
Metilprednisolona/uso terapêutico
Doenças da Boca/terapia
Doenças da Língua/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Histamine H1 Antagonists); 0 (Histamine H2 Antagonists); 5QZO15J2Z8 (Famotidine); 8GTS82S83M (Diphenhydramine); EC 3.4.21.68 (Tissue Plasminogen Activator); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160514
[St] Status:MEDLINE



página 1 de 156 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde